Alzheimer's & Cognition
Conference Coverage
Overanticoagulation in AF boosts dementia risk
Key clinical point: The more time patients with atrial fibrillation who are on warfarin plus aspirin spend with a supratherapeutic INR, the...
Conference Coverage
Leuprolide, acetylcholinesterase inhibitor combo hints at effectiveness for Alzheimer’s
Key clinical point: Leuprolide acetate in combination with an acetylcholinesterase inhibitor was associated with a stabilization of cognition in...
Conference Coverage
Amyloid imaging helped to detect high risk for cognitive decline to Alzheimer’s
Key clinical point: An amyloid PET scan in a patients with MCI could rule out Alzheimer’s as a potential cause of further cognitive decline. Major...
Conference Coverage
Altered mental state is key feature of thyroid storm
Key clinical point: Patients with suspected thyroid storm who present with an altered mental state should be treated aggressively. Major finding:...
News
Alzheimer’s a winner in federal spending bill
Conference Coverage
Dextromethorphan/quinidine mix quells Alzheimer’s anxiety, aggression
Key clinical point: The combination of dextromethorphan and quinidine helped to control agitation and aggression in Alzheimer’s patients. Major...
Conference Coverage
Idalopirdine/donepezil combo boosts cognition in Alzheimer’s
Key clinical point: A combination of an investigational 5-HT6 inhibitor and donepezil could provide a way to increase cognitive function in...
Commentary
Commentary: Managing major neurocognitive disorder in African Americans
News
Diabetes in midlife raises dementia risk
Key clinical point: Primary prevention of diabetes or control of glucose in midlife may protect against cognitive decline later in life.
Conference Coverage
Simple risk score predicts dementia risk in type 2 diabetes
Key clinical point: It’s now readily possible to predict the 10-year dementia risk for individuals with type 2 diabetes.
News
Increased Alzheimer’s risk with long-term benzodiazepine use
Key clinical point: Chronic use of benzodiazepines by the elderly may boost their risk of Alzheimer’s disease in a dose-dependent fashion.